Eliza Ward: Hey — rough question to open with, but: when did you first notice the Foundayo story?
Brian Reed: This morning, Medical Economics. You?
Eliza Ward: Same. Which is strange because the FDA approved Eli Lilly's orforglipron — Foundayo — on April 1st. That's not this morning's news.
Brian Reed: Hold on. April 1st as in six months ago April 1st?
Eliza Ward: Six months ago. Chronic weight management, adults with obesity, expedited FDA review. Approved then, surfacing now.
Brian Reed: And it's the second oral GLP-1 for weight loss — Novo Nordisk's oral Wegovy got there first, December 2025. So Lilly spent six months in second place before anyone really noticed.
Eliza Ward: GLP-1, quick version: it's a hormone your gut releases after a meal to tell your brain you're done eating. These pills just — replicate that signal. Artificially.
Brian Reed: So the body thinks it already ate. That's the whole trick.
Eliza Ward: Right — but that trick was already on shelves before Foundayo existed. Novo Nordisk's oral Wegovy, approved December 2025, had over 600,000 U.S. prescriptions by the time Lilly even launched. So the headline 'first oral GLP-1 pill' — that's not Foundayo. That already happened.
Brian Reed: Six hundred thousand prescriptions in what, three, four months? That's — I mean, that's not a curiosity number. That's a category.
Eliza Ward: That's the point. Oral GLP-1s aren't a novelty anymore. Foundayo is the second mover into a market Novo Nordisk already defined.
Brian Reed: So what does Lilly actually have? Because if the category exists — if oral is already normalized — what's the differentiation argument? Is it just 'ours doesn't require fasting'?
Eliza Ward: That's actually... wait, it's more concrete than it sounds. Oral Wegovy — you take it first thing in the morning, thirty minutes before eating or drinking anything. Foundayo's label says any time of day, no food or drink restrictions. Whether that's a clinical win or a convenience feature, I genuinely don't know yet.
Brian Reed: No, hang on — 'convenience feature' might be underselling it. If Novo's 600,000 prescriptions happened despite a rigid morning fasting window, and Foundayo removes that barrier... that's not nothing.
Eliza Ward: Fair. And the MHRA — UK regulator — approved Foundayo in August 2026, so this has regulatory traction outside the U.S. too. The expedited FDA review got it approved roughly three months after submission, not because the evidence bar was lower, just the timeline was faster. That distinction matters.
Brian Reed: So the real story isn't 'new drug.' It's that oral GLP-1s are now a two-player market — and everything that happens next, pricing, insurance, Medicare coverage — that whole fight happens inside a category that already exists, not around whether the category should.
Eliza Ward: But that's the take I want to push on — because what's already circulating is that Foundayo is a clinical step forward. Not just more convenient. An actual leap. And that's not what the evidence says.
Brian Reed: Which take specifically? Pills are better than pens?
Eliza Ward: That version, yeah. And the injectables — Mounjaro, injectable Wegovy — they still show higher average weight-loss totals. The sources don't quantify the gap, which is its own problem, but the direction is clear. Oral GLP-1s aren't winning on efficacy.
Brian Reed: So what did Deborah Horn actually say? Because her name keeps getting attached to the 'clinical advance' framing.
Eliza Ward: She's the director at McGovern Medical School's obesity center — UTHealth Houston — and what she cited was the dosing flexibility. Specifically that it addresses practical patient challenges. That's a real differentiator. It's just not the same claim as 'better drug.'
Brian Reed: Hang on, so the practical challenge she means is — someone who, I don't know, works an early shift, eats the second they clock in. Oral Wegovy's thirty-minute fasting window is just physically impossible for that person.
Eliza Ward: That's the scenario exactly. And Foundayo's label — any time of day, no food or drink restrictions — that's real. That's adherence. But adherence to a drug that gets you, I mean, let's say less weight loss than a Mounjaro injection would... that's a tradeoff, not a victory.
Brian Reed: No, I don't buy the clean version of either side here. The pill-versus-pen question is genuinely open — we just don't have the delta.
Eliza Ward: Agreed. Convenience is real. Clinical supremacy — not established. And the part that's going to matter more than either of those is what insurers and Medicare actually decide to cover, because that's where the real decision gets made.
Brian Reed: And that's where the access question gets really concrete. Because the coverage decisions aren't made yet — private insurers, completely unresolved. So right now, if you want Foundayo, you're paying out of pocket. Which means $149 a month at the lowest dose, up to $349 at the higher doses.
Eliza Ward: Comparable to oral Wegovy's pricing, for what it's worth.
Brian Reed: Right — so it's not like Lilly undercut anyone. Picture a nursing home activity coordinator, 44, BMI 32, her doctor prescribes Foundayo Friday afternoon. She checks her plan's formulary over the weekend. It's not listed. At all. So she's looking at $149 minimum, every month, indefinitely, before a single insurer has weighed in.
Eliza Ward: That's — yeah, that's the actual story of the approval. It moves the regulatory clock, not the access clock.
Brian Reed: Which brings me to the $98 million. Eli Lilly pulled $98 million in revenue from Foundayo in the first three months. I mean — that's the number everyone's citing as proof of demand.
Eliza Ward: Wait — actually, I want to complicate that immediately. We don't know the gross-to-net after rebates. Pharmaceutical rebates to pharmacy benefit managers can shave that number substantially. The headline revenue figure might be... I mean, it could be half that in real terms. We genuinely don't know.
Brian Reed: So we can't back-calculate how many patients are actually getting the drug.
Eliza Ward: Not cleanly, no. And the Medicare piece — the Trump administration announced a plan where Medicare could cover Foundayo for some patients as soon as summer 2026, copays as low as $50 a month. That's the number that would actually change scale. But that's a proposal. Not enacted policy.
Brian Reed: So the concrete thing to watch isn't the revenue headline — it's whether private insurers follow, and whether that Medicare proposal actually clears into a coverage rule before summer. Those two decisions are where the real trial starts.
Eliza Ward: And that's where I actually land, honestly. The FDA moved. The MHRA moved in August. Eli Lilly moved. Six months in — and the decision that determines whether this is a drug for 10 million Americans or 100,000 of them hasn't been made. By anyone. Private insurers: unresolved. The Medicare $50 copay proposal: still a proposal. That's not a hedge, that's just — that's the actual state of it.
Brian Reed: So regulatory approval, in this case, is almost beside the point? I mean — I don't want to overstate that. The April 1st FDA approval mattered. But for most patients it's... it's a necessary condition, not a sufficient one.
Eliza Ward: Necessary, not sufficient — that's the right frame. And the specific thing I'd watch: whether that Medicare proposal clears into an actual coverage rule before summer 2026. That's the number — $50 copays — that bends the access curve. Everything else is a wait.
Brian Reed: And if it doesn't? Then the oral GLP-1 market just... splits. Insured tier, self-pay tier. Novo Nordisk's 600,000 prescriptions mostly in the self-pay tier already. Foundayo enters the same lane. Which is a market story, not a public health one.
